CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Capital Com Australia Pty Ltd Australia (受监管于 ASIC) Capital Com UK Limited 受监管于 Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (受监管于 CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (受监管于 NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (受监管于 FSA) Capital Com Online Investments Ltd (受监管于 SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
您也可以联系我们： 致电 +44 20 8089 7893 support@capital.com

交易 Recursion Pharmaceuticals, Inc. - RXRX CFD

9.63
3.1%
  • 概括
  • 历史数据
  • 活动
  • 收入报表
  • 资产负债表
  • 现金流
  • 所有权
交易条件
价差 0.07
多头隔夜费

Long position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.030779%
空头隔夜费

Short position overnight fee

Margin. Your investment $1,000.00
隔夜费用 -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
前往平台
-0.013666%
隔夜费时间 22:00 (UTC)
最小交易量 1
货币 USD
保证金 20%
上市交易所 United States of America
交易费 0%

*Information provided by Capital.com

关键数据
前收盘价* 9.34
开盘价* 9.16
1 年变化* -21.78%
日范围* 9.16 - 9.69
52 周范围 4.92-14.18
平均交易量（10 天） 908.18K
平均交易量（3 个月) 25.75M
市值 1.78B
市盈率 -100.00K
流通股 189.56M
收入 28.70M
EPS -1.44
股息（收益率 %） N/A
贝塔 -100.00K
下一个财报发布日期 Mar 21, 2023

所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date 平倉 Change Change (%) 開倉 High Low
Feb 3, 2023 9.63 0.45 4.90% 9.18 9.70 8.99
Feb 2, 2023 9.34 0.79 9.24% 8.55 9.60 8.54
Feb 1, 2023 8.53 0.28 3.39% 8.25 8.67 7.93
Jan 31, 2023 8.29 0.19 2.35% 8.10 8.43 8.10
Jan 30, 2023 8.04 -0.15 -1.83% 8.19 8.48 7.95
Jan 27, 2023 8.49 0.41 5.07% 8.08 8.65 8.08
Jan 26, 2023 8.17 -0.08 -0.97% 8.25 8.28 7.91
Jan 25, 2023 8.18 -0.14 -1.68% 8.32 8.32 7.71
Jan 24, 2023 8.56 0.15 1.78% 8.41 8.84 8.32
Jan 23, 2023 8.67 0.13 1.52% 8.54 8.92 8.24
Jan 20, 2023 8.61 -0.01 -0.12% 8.62 8.68 8.33
Jan 19, 2023 8.43 -0.19 -2.20% 8.62 8.84 8.22
Jan 18, 2023 8.90 -0.32 -3.47% 9.22 9.45 8.90
Jan 17, 2023 9.15 0.15 1.67% 9.00 9.44 8.85
Jan 13, 2023 8.64 0.18 2.13% 8.46 8.97 8.37
Jan 12, 2023 8.67 0.85 10.87% 7.82 8.68 7.68
Jan 11, 2023 7.89 0.21 2.73% 7.68 7.96 7.60
Jan 10, 2023 7.75 0.36 4.87% 7.39 7.81 7.38
Jan 9, 2023 7.49 0.01 0.13% 7.48 7.85 7.36
Jan 6, 2023 7.40 0.07 0.95% 7.33 7.51 7.03

Recursion Pharmaceuticals, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • 年度
  • 每季度
2019 2020 2021
总收入 2.319 3.962 10.178
收入 2.319 3.962 10.178
总营业费用 65.315 89.46 193.78
销售/一般/行政费用，总计 19.898 27.035 66.671
研究与开发 44.862 61.542 125.978
异常费用（收入） 0.555 0.883 0.827
营业收入 -62.996 -85.498 -183.602
利息收入（费用），非经营净值 1.106 -1.024 -2.879
其他，净值 0.011 -0.484 0.002
税前净收入 -61.879 -87.006 -186.479
税后净收入 -61.879 -87.006 -186.479
未计算非常项目前的净收益 -61.879 -87.006 -186.479
净收入 -61.879 -87.006 -186.479
普通股股东可获收益 (不含非经常性项目) -61.879 -87.006 -186.479
普通股股东可获收益 (含非經常性項目) -61.879 -87.006 -186.479
摊薄净收入 -61.879 -87.006 -186.479
摊薄后加权平均股 162.155 162.155 125.348
扣除特别项目的每股摊薄盈利 -0.3816 -0.53656 -1.48769
Dividends per Share - Common Stock Primary Issue 0 0
每股正常摊薄盈利 -0.37818 -0.53111 -1.48109
Depreciation / Amortization 0.304
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
总收入 2.562 2.549 2.534 2.533 5.333
收入 2.562 2.549 2.534 2.533 5.333
总营业费用 33.046 43.478 49.763 67.493 61.314
销售/一般/行政费用，总计 8.937 13.854 15.69 21.419 21.074
研究与开发 24.033 29.548 33.17 45.998 32.365
Depreciation / Amortization 0.076 0.076 0.076 0.076 0.076
营业收入 -30.484 -40.929 -47.229 -64.96 -55.981
利息收入（费用），非经营净值 -0.233 -2.472 -0.17 -0.002 0.073
税前净收入 -30.717 -43.401 -47.428 -64.933 -55.979
税后净收入 -30.717 -43.401 -47.428 -64.933 -55.979
未计算非常项目前的净收益 -30.717 -43.401 -47.428 -64.933 -55.979
净收入 -30.717 -43.401 -47.428 -64.933 -55.979
普通股股东可获收益 (不含非经常性项目) -30.717 -43.401 -47.428 -64.933 -55.979
普通股股东可获收益 (含非經常性項目) -30.717 -43.401 -47.428 -64.933 -55.979
摊薄净收入 -30.717 -43.401 -47.428 -64.933 -55.979
摊薄后加权平均股 168.321 138.361 168.534 169.853 170.69
扣除特别项目的每股摊薄盈利 -0.18249 -0.31368 -0.28142 -0.38229 -0.32796
Dividends per Share - Common Stock Primary Issue 0 0 0 0
每股正常摊薄盈利 -0.18249 -0.31368 -0.27651 -0.38229 -0.32796
异常费用（收入） 0.827 0
其他，净值 -0.029 0.029 -0.071
收入成本，共计 7.799
毛利 -2.466
  • 年度
  • 每季度
2019 2020 2021
流动资产总额 76.398 266.437 534.718
现金和短期投资 69.883 262.126 516.562
现金等价物 69.883 262.126 285.116
应收账款总额，净额 0.151 0.156 9.09
Accounts Receivable - Trade, Net 0.151 0.156 0.034
Other Current Assets, Total 6.364 4.155 9.066
Total Assets 101.431 298.585 610.345
Property/Plant/Equipment, Total - Net 24.37 25.967 64.725
Property/Plant/Equipment, Total - Gross 30.085 35.929 83.462
Accumulated Depreciation, Total -5.715 -9.962 -18.737
Intangibles, Net 0 1.689 1.385
Other Long Term Assets, Total 0.663 3.691 8.716
Total Current Liabilities 6.684 23.099 46.658
Accounts Payable 1.261 1.074 2.819
Accrued Expenses 5.346 10.952 33.749
Notes Payable/Short Term Debt 0 0 0
Current Port. of LT Debt/Capital Leases 0.077 1.073 0.09
Other Current Liabilities, Total 0 10 10
Total Liabilities 24.587 56.562 67.407
Total Long Term Debt 12.418 11.414 0.633
Long Term Debt 12.418 11.414 0.633
Other Liabilities, Total 5.485 22.049 20.116
Total Equity 76.844 242.023 542.938
Preferred Stock - Non Redeemable, Net 201.109 448.312 0
Common Stock 0 0 0.002
Additional Paid-In Capital 2.33 7.312 943.142
Retained Earnings (Accumulated Deficit) -126.595 -213.601 -400.08
Total Liabilities & Shareholders’ Equity 101.431 298.585 610.345
Total Common Shares Outstanding 162.155 162.155 170.272
短期投资 0 231.446
Goodwill, Net 0.801 0.801
Other Equity, Total 0 -0.126
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
流动资产总额 221.822 647.635 600.87 534.718 619.455
现金和短期投资 214.088 632.738 578.91 516.562 591.105
现金等价物 214.088 632.738 394.721 285.116 507.891
应收账款总额，净额 0.071 0.049 2.282 9.09 11.397
Accounts Receivable - Trade, Net 0.071 0.049 0.034 0.034 0.034
Other Current Assets, Total 7.663 14.848 19.678 9.066 16.953
Total Assets 271.943 698.59 658.606 610.345 734.319
Property/Plant/Equipment, Total - Net 44.642 48.549 55.439 64.725 104.005
Property/Plant/Equipment, Total - Gross 56.036 62.306 71.662 83.462 125.433
Accumulated Depreciation, Total -11.394 -13.757 -16.223 -18.737 -21.428
Intangibles, Net 2.414 2.338 2.262 1.385 1.309
Other Long Term Assets, Total 3.065 0.068 0.035 8.716 8.749
Total Current Liabilities 26.854 29.54 42.943 46.658 85.705
Accounts Payable 3.125 3.196 6.326 2.819 4.162
Accrued Expenses 11.584 13.209 26.529 33.749 27.204
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.145 3.135 0.088 0.09 0.092
Other Current Liabilities, Total 10 10 10 10 54.247
Total Liabilities 56.662 55.876 59.574 67.407 240.753
Total Long Term Debt 10.339 9.423 0.656 0.633 0.61
Long Term Debt 10.339 9.423 0.656 0.633 0.61
Other Liabilities, Total 19.469 16.913 15.975 20.116 154.438
Total Equity 215.281 642.714 599.032 542.938 493.566
Redeemable Preferred Stock 450.85
Preferred Stock - Non Redeemable, Net -2.538 0 0 0
Common Stock 0 0.002 0.002 0.002 0.002
Additional Paid-In Capital 11.287 930.431 934.175 943.142 949.932
Retained Earnings (Accumulated Deficit) -244.318 -287.719 -335.147 -400.08 -456.059
Total Liabilities & Shareholders’ Equity 271.943 698.59 658.606 610.345 734.319
Total Common Shares Outstanding 168.321 168.426 168.635 170.272 171.078
短期投资 184.189 231.446 83.214
Other Equity, Total 0.002 -0.126 -0.309
Goodwill, Net 0.801 0.801
  • 年度
  • 每季度
2019 2020 2021
净收入/起跑线 -61.879 -87.006 -186.479
经营活动产生的现金 -57.042 -45.399 -158.614
经营活动产生的现金 3.543 4.442 8.405
非现金物品 0.886 6.331 19.766
已付现金利息 0.485 0.989 0.68
营运资金的变化 0.408 30.834 -0.306
投资活动产生的现金 -3.91 -8.74 -271.744
资本支出 -3.91 -5.831 -39.798
其他投资现金流量项目，总计 0 -2.909 -231.946
融资活动产生的现金 120.41 246.135 458.54
融资现金流项目 -0.275 0 0
股票的发行（报废），净额 119.98 239.812 471.338
债务的发行（退还），净额 0.705 6.323 -12.798
现金净变化 59.458 191.996 28.182
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -30.717 -74.118 -121.546 -186.479 -55.979
Cash From Operating Activities -30.755 -64.408 -97.456 -158.614 77.388
Cash From Operating Activities 1.402 3.733 6.169 8.405 2.767
Non-Cash Items 1.922 9.614 14.268 19.766 7.776
Cash Interest Paid 0.254 0.54 0.665 0.68 0.014
Changes in Working Capital -3.362 -3.637 3.653 -0.306 122.824
Cash From Investing Activities -19.416 -25.628 -219.501 -271.744 143.304
Capital Expenditures -19.416 -25.628 -35.334 -39.798 -4.342
Cash From Financing Activities 2.134 465.839 454.744 458.54 2.084
Issuance (Retirement) of Stock, Net 2.154 465.879 462.901 471.338 2.106
Issuance (Retirement) of Debt, Net -0.02 -0.04 -12.777 -12.798 -0.022
Net Change in Cash -48.037 375.803 137.787 28.182 222.776
Other Investing Cash Flow Items, Total 0 -184.167 -231.946 147.646
Financing Cash Flow Items 4.62
投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
Baillie Gifford & Co. Investment Advisor 13.6608 24820850 3226157 2022-12-31 LOW
Mubadala Investment Company PJSC Sovereign Wealth Fund 11.4375 20781376 535976 2023-01-26 LOW
Lux Capital Management, LLC Venture Capital 7.1667 13021519 0 2022-03-31 LOW
DCVC Management Co, LLC Venture Capital 5.4444 9892261 0 2022-09-30 LOW
MIC Capital Management UK LLP Investment Advisor 4.6516 8451758 0 2022-09-30 HIGH
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.6084 8373178 1393519 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.5728 8308494 1476128 2022-09-30 LOW
Kinnevik AB Venture Capital 4.212 7653061 7653061 2022-12-31 LOW
Borgeson (Blake Charles) Individual Investor 4.1894 7611827 -16445 2023-01-24 LOW
Laurion Capital Management LP Hedge Fund 2.5247 4587274 0 2022-09-30 HIGH
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.5074 4555759 2430027 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 2.3397 4251164 1415312 2022-09-30 LOW
Obvious Ventures Venture Capital 2.1933 3985087 -1992544 2022-09-30 LOW
Li (Dean Y) Individual Investor 2.0937 3804102 1573 2023-01-03 LOW
AllianceBernstein L.P. Investment Advisor/Hedge Fund 1.7818 3237344 -363616 2022-09-30 LOW
ARK Investment Management LLC Investment Advisor 1.7059 3099490 -260321 2022-12-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.2835 2332083 826087 2022-09-30 LOW
Platinum Asset Management Investment Advisor/Hedge Fund 1.2394 2251971 -283651 2022-09-30 LOW
Menlo Ventures Venture Capital 1.0853 1971908 0 2022-12-31 MED
Credit Suisse Asset Management Investment Advisor/Hedge Fund 0.861 1564459 -340 2022-09-30 LOW

为什么选择 Capital.com？让我们的数字来说话。

Capital.com Group
+485000+

交易者

65000+

每月活跃客户

$48000000+

每月投资额

$28000000+

每月提取金额

交易計算器

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

貿易佣金
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
杠杆
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
投資
交易規模（槓桿 x 投資）：
開倉

平倉

做空 做多
過去的表現並不是未來結果的可靠指標
盈利/失利

Recursion Pharmaceuticals, Inc. Company profile

关于 Recursion Pharmaceuticals Inc.

Recursion Pharmaceuticals, Inc.是一家处于临床阶段的生物技术公司。 公司使用Recursion操作系统（Recursion OS），这是一个多层系统，用于生成、分析并从生物和化学数据集中获得洞察力。 它由三部分组成。 基础设施层、Recursion数据宇宙和Recursion地图。 其项目包括REC-4881、REC-3599、REC-2282、REC-994、治疗艰难梭菌结肠炎的先导分子、治疗神经炎症的先导分子、治疗巴顿病的先导分子和治疗CMT2A的先导分子。

Industry: Bio Therapeutic Drugs

41S Rio Grande Street
SALT LAKE CITY
UTAH 84101
US

收入报表

  • Annual
  • Quarterly

人们也观看

BTC/USD

23,374.60 Price
-0.380% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 60.00

US100

12,566.80 Price
-0.450% 1D Chg, %
多头隔夜费 -0.0183%
空头隔夜费 0.0071%
隔夜费时间 22:00 (UTC)
价差 3.0

Oil - Crude

73.41 Price
-3.570% 1D Chg, %
多头隔夜费 -0.0223%
空头隔夜费 0.0065%
隔夜费时间 22:00 (UTC)
价差 0.03

XRP/USD

0.41 Price
-0.130% 1D Chg, %
多头隔夜费 -0.0500%
空头隔夜费 0.0140%
隔夜费时间 22:00 (UTC)
价差 0.00321

还在找一位您可以信任的经纪商吗？

加入成为全球485,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易